Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976542 | 0.86 | POLB (0.65) | POLBCYP2C19MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2002157 | 0.86 | POLB (0.61) | POLBCYP2C19MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12833234 | 0.84 | RXFP1 (0.63) | POLBCYP2C19MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL855339 | 0.84 | POLB (0.60) | POLBCYP2C19MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30073359 | 0.84 | POLB (0.60) | POLBCYP2C19MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL13149251 | 0.83 | ALDH1A1 (0.68) | POLBCYP2C19SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11204339 | 0.82 | HTT (0.50) | POLBMAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL3764825 | 0.82 | POLB (0.61) | POLBCYP2C19MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3764827 | 0.81 | POLB (0.60) | POLBCYP2C19MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1863115 | 0.81 | POLB (0.63) | POLBCYP2C19MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2186516-B1 | Novel benzazepine derivative | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| US-7947718-B2 | Isoxazole compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| EP-2186516-A1 | Novel benzazepine derivative | Glaxo Group Limited (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | US | disclosed |
| EP-2133340-A1 | Novel benzazepine derivatives | Glaxo Group Limited (GB) | 2009-12-16 | — | — | EP | disclosed |
| EP-1572215-B1 | BENZO[D]AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | disclosed |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-11 | — | — | US | disclosed |
| US-7423147-B2 | Pyridine compounds as histamine H3 modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| EP-1761496-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005097751-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | HRH3, HRH4, HRH1 | POLB 4585/4885CYP2C19 1596/4885MAPT 1536/4885 |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | HRH3, HRH4, HRH2 | POLB 4797/4885CYP2C19 1290/4885MAPT 1614/4885 |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | HRH3, HRH4, HRH2 | POLB 4797/4885CYP2C19 1290/4885MAPT 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.